Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance.

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Pharmacology

Background:

• Despite effective LDL cholesterol reduction, residual cardiovascular risk persists.
• Elevated triglycerides (TGs) and TG-rich lipoproteins are key contributors to this residual risk.
• Apolipoprotein C-III (apoC-III) plays a critical role in regulating TG metabolism and lipoprotein clearance.

Purpose of the Study:

• To investigate the role of apolipoprotein C-III (apoC-III) in cardiovascular disease (CVD) risk.
• To evaluate novel therapeutic strategies targeting apoC-III for TG reduction.
• To assess the potential of apoC-III inhibition in managing residual cardiovascular risk.

Main Methods:

• Review of genetic studies linking APOC3 gene variants to TG levels and coronary heart disease risk.
• Analysis of current hypolipidemic drug efficacy in TG reduction.
• Examination of emerging therapeutics specifically targeting apoC-III, including antisense oligonucleotides, small interfering RNA, and monoclonal antibodies.

Main Results:

• Genetic evidence confirms a causal role for apoC-III in CVD.
• Loss-of-function mutations in APOC3 are associated with lower TGs and reduced coronary heart disease risk.
• New drugs targeting apoC-III demonstrate potential for substantial TG reductions, exceeding current therapies.

Conclusions:

• Apolipoprotein C-III is a validated therapeutic target for managing hypertriglyceridemia and reducing cardiovascular risk.
• Targeting apoC-III represents a significant advancement in addressing residual CV risk beyond LDL-C lowering.
• Novel apoC-III-targeted therapies offer a promising avenue for improved patient outcomes in cardiovascular disease prevention.